FATE
Fate Therapeutics, Inc.NASDAQHealthcare$1.22-1.61%ClosedMarket Cap: $141.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
0.68
P/S
20.82
EV/EBITDA
-1.21
DCF Value
$-0.48
FCF Yield
-81.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-94.1%
Operating Margin
-2222.4%
Net Margin
-2051.1%
ROE
-55.0%
ROA
-42.7%
ROIC
-51.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $1.4M | -842.4% | $-34.7M | $-32.4M | $-0.27 | — |
| FY 2025 | $6.6M | -94.1% | $-147.7M | $-136.3M | $-1.15 | — |
| Q3 2025 | $1.7M | 100.0% | $-34.7M | $-32.3M | $-0.27 | — |
| Q2 2025 | $1.9M | 100.0% | $-37.0M | $-34.1M | $-0.29 | — |
| Q1 2025 | $1.6M | 100.0% | $-41.3M | $-37.6M | $-0.32 | — |
| Q4 2024 | $1.9M | 100.0% | $-61.7M | $-52.2M | $-0.44 | — |
| FY 2024 | $13.6M | 100.0% | $-210.3M | $-186.3M | $-1.64 | — |
| Q3 2024 | $3.1M | 100.0% | $-52.4M | $-47.7M | $-0.40 | — |
| Q2 2024 | $6.8M | 30.3% | $-45.1M | $-38.4M | $-0.33 | — |
| Q1 2024 | $1.9M | -150.4% | $-51.1M | $-48.0M | $-0.47 | — |
| Q4 2023 | $1.7M | -191.5% | $-48.1M | $-44.1M | $-0.45 | — |
| FY 2023 | $63.5M | -147.4% | $-190.5M | $-160.9M | $-1.64 | — |